Table 2 Treatment characteristics and follow-up of 93 patients with idiopathic inflammatory myopathies
Characteristics | Anti-PM/Scl(+) (n = 16) | Anti-PM/Scl(-) (n = 77) | p value |
|---|---|---|---|
Current follow-up | |||
Duration of follow-up (months) | 94 (20–140) | 64 (65–93) | 0.244 |
Infections | 2 (12.5) | 21 (27.3) | 0.341 |
Relapses | 11 (68.8) | 26 (33.8) | 0.023 |
Death | 1 (6.3) | 1 (1.3) | 0.402 |
Disease status at the last medical evaluation | |||
Active disease (clinical relapse) | 8 (50.0) | 19 (24.7) | 0.025 |
Complete clinical response | 6 (37.5) | 21 (27.3) | |
Disease remission | 2 (12.5) | 37(48.0) | |
Treatment | |||
Previous IVMP pulse therapy | 5 (31.2) | 12 (15.6) | 0.235 |
Previous IVIg | 0 | 5 (6.5) | - |
Previous IVIg + IVMP pulse therapy | 3 (18.8) | 21 (27.3) | 0.478 |
No IVMP or IVIg | 8 (50.0) | 39 (50.6) | 0.962 |
Current treatment | |||
Glucocorticoid | |||
Current use | 7 (43.8) | 21 (27.3) | 0.134 |
Current dose (mg/day) | 10 (5–20) | 10 (5–20) | 0.534 |
Methotrexate | 6 (37.5) | 10 (13.0) | 0.027 |
Azathioprine | 5 (31.2) | 8 (10.4) | 0.029 |
Mycophenolate mofetil | 4 (25.0) | 13 (16.9) | 0.696 |
Leflunomide | 0 | 4 (5.2) | - |
Cyclosporine | 5 (31.2) | 22 (28.6) | 0.823 |
Cyclophosphamide | 3 (18.8) | 7 (9.1) | 0.256 |
Rituximab | 4 (25.0) | 8 (10.4) | 0.113 |